File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: Studying the effects of new peritoneal dialysis solutions on the peritoneum

TitleStudying the effects of new peritoneal dialysis solutions on the peritoneum
Authors
Issue Date2007
PublisherMultimed, Inc. The Journal's web site is located at http://pdiconnect.com
Citation
The 11th Congress of the International Society of Peritoneal Dialysis, Hong Kong, 25–29 August 2006. In Peritoneal Dialysis International, 2007, v. 27 SUPPL. 2, p. S87-S93 How to Cite?
Abstract◆ Background: Compelling data underscore the bioincompatible nature of glucose-based peritoneal dialysis (PD) solutions and their detrimental effects on peritoneal physiology and morphology. New PD solutions have been formulated to tackle common clinical problems such as inadequate ultrafiltration or malnutrition, and to improve biocompatibility - the latter aimed at preserving the structural and functional integrity of the peritoneum and reducing adverse systemic effects on the patient. ◆ Methods: This article reviews the factors in PD fluids that alter normal peritoneal anatomy and physiology, and the data that illustrate approaches to investigating the local and systemic biocompatibility of new PD solutions. ◆ Results: Chronic exposure of the peritoneal membrane to glucose-based PD solutions results in denudation of the mesothelium, thickened submesothelium, and hyalinization of the vasculature, often resulting in reduced or lost solute and water clearance. Data from in vitro or animal experiments and clinical studies have shown improved biocompatibility profiles with new PD solutions that are glucose-free (that is, dialysates with amino acids or icodextrin), bicarbonate-buffered, or compartmentalized during heat sterilization to reduce levels of glucose degradation products. Improved biocompatibility is denoted by reduced induction of proinflammatory, profibrotic, or angiogenic growth factors in mesothelial cells and macrophages, or by less perturbation of leukocyte phagocytic function. ◆ Conclusions: Data from in vitro and animal experiments show more favorable biocompatibility profiles with new PD fluids than with glucose-based dialysates. Clinical studies are ongoing to assess the impact of the new PD fluids on peritoneal function, morbidity, and mortality. Copyright © 2007 International Society for Peritoneal Dialysis. Printed in Canada. All rights reserved.
Persistent Identifierhttp://hdl.handle.net/10722/163569
ISSN
2015 Impact Factor: 1.298
2015 SCImago Journal Rankings: 0.683
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorChan, THen_US
dc.contributor.authorYung, Sen_US
dc.date.accessioned2012-09-05T05:37:28Z-
dc.date.available2012-09-05T05:37:28Z-
dc.date.issued2007en_US
dc.identifier.citationThe 11th Congress of the International Society of Peritoneal Dialysis, Hong Kong, 25–29 August 2006. In Peritoneal Dialysis International, 2007, v. 27 SUPPL. 2, p. S87-S93en_US
dc.identifier.issn0896-8608en_US
dc.identifier.urihttp://hdl.handle.net/10722/163569-
dc.description.abstract◆ Background: Compelling data underscore the bioincompatible nature of glucose-based peritoneal dialysis (PD) solutions and their detrimental effects on peritoneal physiology and morphology. New PD solutions have been formulated to tackle common clinical problems such as inadequate ultrafiltration or malnutrition, and to improve biocompatibility - the latter aimed at preserving the structural and functional integrity of the peritoneum and reducing adverse systemic effects on the patient. ◆ Methods: This article reviews the factors in PD fluids that alter normal peritoneal anatomy and physiology, and the data that illustrate approaches to investigating the local and systemic biocompatibility of new PD solutions. ◆ Results: Chronic exposure of the peritoneal membrane to glucose-based PD solutions results in denudation of the mesothelium, thickened submesothelium, and hyalinization of the vasculature, often resulting in reduced or lost solute and water clearance. Data from in vitro or animal experiments and clinical studies have shown improved biocompatibility profiles with new PD solutions that are glucose-free (that is, dialysates with amino acids or icodextrin), bicarbonate-buffered, or compartmentalized during heat sterilization to reduce levels of glucose degradation products. Improved biocompatibility is denoted by reduced induction of proinflammatory, profibrotic, or angiogenic growth factors in mesothelial cells and macrophages, or by less perturbation of leukocyte phagocytic function. ◆ Conclusions: Data from in vitro and animal experiments show more favorable biocompatibility profiles with new PD fluids than with glucose-based dialysates. Clinical studies are ongoing to assess the impact of the new PD fluids on peritoneal function, morbidity, and mortality. Copyright © 2007 International Society for Peritoneal Dialysis. Printed in Canada. All rights reserved.en_US
dc.languageengen_US
dc.publisherMultimed, Inc. The Journal's web site is located at http://pdiconnect.comen_US
dc.relation.ispartofPeritoneal Dialysis Internationalen_US
dc.subject.meshAmino Acidsen_US
dc.subject.meshAnimalsen_US
dc.subject.meshBicarbonatesen_US
dc.subject.meshBiocompatible Materialsen_US
dc.subject.meshBuffersen_US
dc.subject.meshDialysis Solutions - Chemistry - Pharmacologyen_US
dc.subject.meshGlucansen_US
dc.subject.meshGlucoseen_US
dc.subject.meshHumansen_US
dc.subject.meshPeritoneal Dialysisen_US
dc.subject.meshPeritoneum - Drug Effectsen_US
dc.titleStudying the effects of new peritoneal dialysis solutions on the peritoneumen_US
dc.typeConference_Paperen_US
dc.identifier.emailChan, TH:dtmchan@hku.hken_US
dc.identifier.emailYung, S:ssyyung@hku.hken_US
dc.identifier.authorityChan, TH=rp00394en_US
dc.identifier.authorityYung, S=rp00455en_US
dc.description.naturelink_to_OA_fulltexten_US
dc.identifier.pmid17556337-
dc.identifier.scopuseid_2-s2.0-35748986444en_US
dc.identifier.hkuros130440-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-35748986444&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume27en_US
dc.identifier.issueSUPPL. 2en_US
dc.identifier.spageS87en_US
dc.identifier.epageS93en_US
dc.identifier.isiWOS:000257889500017-
dc.publisher.placeCanadaen_US
dc.description.otherThe 11th Congress of the International Society of Peritoneal Dialysis, Hong Kong, 25–29 August 2006. In Peritoneal Dialysis International, 2007, v. 27 SUPPL. 2, p. S87-S93-
dc.identifier.scopusauthoridChan, TH=7402687700en_US
dc.identifier.scopusauthoridYung, S=22636568800en_US
dc.customcontrol.immutablejt 130827-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats